

18/ 308
10/17/01
PATENT

Attorney Docket No. 3495.0111-10
Customer No. 22,852

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:)
Bernard DUJON et al.) Group Art Unit: 1633
Serial No.: 09/244,130) Examiner: KAUSHAL, S.
Filed: February 4, 1999)

For: NUCLEOTIDE SEQUENCE ENCODING
THE ENZYME I-SCEI AND THE USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO PAPER NO. 15

RECEIVED
OCT 15 2001
TECH CENTER 1600/2900

In response to the Office Action dated April 11, 2001 (Paper No. 15), the period for response to which has been extended by filing a petition for three month extension of time concurrently herewith, applicants submit the following remarks.

REMARKS

Reconsideration of this application is respectfully requested.

Applicants thank Examiner Kaushal and Primary Examiner Clark for the courtesy of the Interview on June 20, 2001.

Claims 53-57 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 15, 28-30, and 32 of copending Application No. 08/643,732. Since this is a provisional rejection, applicants respectfully request that the rejection be held in abeyance.

Claims 48-93 were rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing subject matter that was not described in the specification in such a way as to

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000